GATR-3

Table 2: GATR-3 MIC against A. baumannii AB5075 is 4 µg/mL.

Table 2: GATR-3 MIC against A. baumannii BAA-1710 is 4 µg/mL.

Table 2: GATR-3 MIC against A. baumannii BAA-1794 is 4 µg/mL.

Table 2: GATR-3 MIC against A. baumannii BAA-1795 is 4 µg/mL.

Table 2: GATR-3 MIC against A. baumannii BAA-1797 is 4 µg/mL.

Table 2: GATR-3 MIC against A. baumannii BAA-1799 is 4 µg/mL.

Table 2: GATR-3 MIC against A. baumannii BAA-1800 is 4 µg/mL.

Table 2: GATR-3 MIC against A. baumannii BAA-1605 is 4 µg/mL.

Table 2: GATR-3 MIC against P. aeruginosa BAA-2110 is 8 µg/mL.

Table 2: GATR-3 MIC against K. pneumoniae BAA-1705 is 8 µg/mL.

Table 2: GATR-3 MIC against E. asburiae BAA-3043 is 32 µg/mL.

Table 2: GATR-3 MIC against E. faecalis 51299 is 64 µg/mL.

Table 2: GATR-3 MIC against MRSA (S. aureus 33592) is 64 µg/mL.

Section 2.2: 'The minimum bactericidal concentration (MBC) was determined to be 4 µg/mL after plating each well which showed no growth in the MIC assay on an agar plate, suggesting that GATR-3 is bactericidal at the MIC.'

Table 3: GATR-3 MBIC50 against A. baumannii BAA-1794 is 0.62 µg/mL (95% CI 0.3 to 1.2).

Table 3: GATR-3 MBIC50 against A. baumannii AB5075 is 9.3 µg/mL (95% CI 0.5 to 179.4).

Table 3: GATR-3 MBIC50 against A. baumannii BAA-1710 is 7.4 µg/mL (95% CI 3 to 18.3).

Table 3: GATR-3 MBIC50 against A. baumannii BAA-1795 is 0.91 µg/mL (95% CI 0.6 to 1.38).

Table 3: GATR-3 MBIC50 against A. baumannii BAA-1797 is 0.18 µg/mL (95% CI 0.11 to 0.28).

Table 3: GATR-3 MBIC50 against A. baumannii BAA-1605 is 21.7 µg/mL (95% CI 4.25 to 110.5).

Table 3: GATR-3 MBIC50 against A. baumannii BAA-1800 is 8.8 µg/mL (95% CI 3.46 to 22.15).

Table 4: GATR-3 MBEC50 against A. baumannii BAA-1794 is 9.6 µg/mL (95% CI 4 to 23).

Table 4: GATR-3 MBEC50 against A. baumannii AB5075 is 4.8 µg/mL (95% CI 2.72 to 8.47).

Table 4: GATR-3 MBEC50 against A. baumannii BAA-1710 is 8 µg/mL.

Table 4: GATR-3 MBEC50 against A. baumannii BAA-1795 is >64 µg/mL.

Table 4: GATR-3 MBEC50 against A. baumannii BAA-1797 is 6 µg/mL (95% CI 2.85 to 12.8).

Table 4: GATR-3 MBEC50 against A. baumannii BAA-1605 is 4.4 µg/mL (95% CI 2.42 to 8).

Table 4: GATR-3 MBEC50 against A. baumannii BAA-1800 is 4.1 µg/mL (95% CI 2.72 to 6.2).

Figure 1A: GATR-3 completely eradicated MDR A. baumannii AB5075 preformed biofilms at 32 µg/mL.

Section 2.9: 'we observed ~50% hemolysis of human blood at 5000 µg/mL (5 mg/mL) GATR-3 peptide. Thus, the HC50 concentration was determined to be 5000 µg/mL.'

Table 5 caption: 'MHC (95% CI) = 595 µg/mL (339–825)'.

Section 2.8.1: 'GATR-3 showed no hemolysis at any of the peptide concentrations tested.' (up to 100 µg/mL).

Section 2.8.2: 'GATR-3 demonstrates 95.8% cell viability at 100 µg/mL.'

Section 2.8.3: 'The GATR-3-treated group demonstrated 90% survival... Each larva was injected with 10 µg of GATR-3 dissolved in 10 µL of PBS (1 mg/mL).'

Table 5: MHC Therapeutic Index (MHC/MIC) for GATR-3 against A. baumannii is 149.

Table 5: HC50 Therapeutic Index (HC50/MIC) for GATR-3 against A. baumannii is 1250.